INTRAVESICAL INSTILLATION THERAPY IN THE TREATMENT OF SUPERFICIAL BLADDER CARCINOMA
Authors:
K. Karmašová; V. Vít; D. Pacík
Authors‘ workplace:
Urologická klinika, FN Brno
Published in:
Urol List 2011; 9(3): 22-26
Overview
Bladder tumours represent a challeging topic regarding both the adequate and early diagnostics and choice of suitable therapy. The author presents an overview of intravesical therapy options including the recommended schedules and comparison of individual modalities.
Key words:
transitional cell tumors, intravesical chemoterapy, intravesical immunotherapy
Sources
1. UZIS 2011; www.svod.cz
2. Ro JY, Staerkel GA, Ayala AG. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 1992; 19(3): 435–453.
3. Lopez-Beltran A, Cheng L, Anderson L et al. Preneoplastic non-papilary conditions of the urinary bladder. Virchow Arch 2002; 440(1): 3–11.
4. Epstein J, Amin M, Reuter V et al. The Word Health Organisation/International Society of Urological pathology konsensus classification of urothelial neoplasms of the urinary bladder. Am Surg Pathol 1998; 22(12): 1435–1448.
5. Young R, Eble J. Unusual forms of carcinoma of urinary bladder. Hum Pathol 1991; 22(10): 948–965.
6. Dušková J. Patologie reaktivních změn, dysplazií a nádorů močového měchýře. Onkourologie. Praha: Karolinum 2005.
7. Holmang S, Hedelin H, Anderström C et al. The importance of depth of invasion in stage T1 of bladder carcinoma. A prospective study. J Urol 1197; 157(3): 800–804.
8. Cheng L, Cheville J, Neumann R et al. Survival of patiens with carcinoma in situ of urinary bladder. Cancer 1999; 85(11): 2469–2474.
9. Oesterlinck W, Lobel B, Jakse G et al. Guidelines on bladder cancer. Eur Urol 2002; 41(2): 105–112.
10. Czerniak B, Chatuverdi V, Li L et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia. Implications for a genetic model fo multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 1999; 18(5): 1185–1196.
11. Tomson C, Porter T. Asymptomatic microscopic or dipstic haematuria in adults. Which investigation for which patients? A review of evidence. Br J Urol Int 2002; 90(3): 185–198.
12. Soloway M, Sofer M, Vaidya A et al. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167(4): 1573–1583.
13. Millan- Rodriguez F, Chechile-Toniolo G, Slavador-Bayarri J et al. Primary superficial bladder cancer risk Gross accroding to progression, mortality et recurence. J Urol 2000; 164 (3 Pt 1): 680–684.
14. Trasher JB, Crawford E. Compliacations of intravesical chemotherapy. Urol Clin North Am 1992; 19(3): 529–539.
15. Ali-El-Dein B, El-Baz M, Aly A et al. Intravesical epirubicin versus doxorubicin for superficial bladder tumors(stages pTa and pT1) A randomized prospective study. J Urol 1997; 158(1): 68–74.
16. Boehle A, Jocham D, Bock P. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer. A formal meta-analysis of komparative studies on recurrence nad toxicity. J Urol 2003; 169(1): 90–96.
17. Witjes JA, van der Heijden AG, Vriesem JL et al. Intravesical gemcitabin: a phase 1 and pharmacokinetic study. Eur Urol 2004; 45(2): 182–186.
18. Oesterlinck W, Kurth KH, Schroder F et al. A prospective European Organisation for Research and Treatment of Cancer genitourinary group randomized trail comparing transurethral followed by a single intravesical instilation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149(4): 749–752.
19. Babjuk M, Oesterlinck W, Sylvester R et al. EAU Gulidelines on Ta T1 (Non-muscle invasive) Bladder cancer 2008: 1–22.
20. Kliment J. Intravezikálna imunoterapia. In: Ondruš D et al. Nádory močového mechúra diagnostika a liečba. Martin: Osveta 2000. 215–231.
21. Morales A, Chin J, Ramsey E. Mycobacterial cell wal extract for treatment of carcinoma in situ of the bladder. J Urol 2001; 166(5): 1633–1638.
22. Belldegruin A, Franklin J, Donnel E et al. Superficial bladder cancer: the role of interferon alfa. J Urol 1998; 159(6): 1793–1801.
23. Morales A, Edinger D, Bruce A. Intracavi-tary bacilus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116(2): 180–182.
24. Bohle A, Jocham D. Intravesical Imunotherapy with Bacillus Calmette-Guerin facts, figures, and results. 2000. Urban & Fischer Verlag, Munchen, Jena.
25. Lamm DL, Blumenstein BA, Crissmann J et al. Maintenance bacillus Calmette-Guerin immunitherapy for recurrent TaT1 and carcinoma in situ transitional cell carcinoma of the bladder. A randomised sputhwest oncology group study. J Urol 2000; 163(4): 1124–1129.
26. Kaasinen E, Wijkstrom H, Malmstrom P et al. Alternating mitomycin C a BCG instilations versus BCG alone in tretament of carcinoma in situ of urinary bladder. A nordic stury. Eur Urol 2003; 43(6): 637–645.
27. O´Donnell MA. Treatment of Bacillus Calmette-Guerin Failures in patient with high-risk non-muscle Invasive Bladder Cancer. Genitourinary Cancers Symphosium Proceedings Book 2008: 55–56.
28. Alcaraz A. Bladder Cancer: Highlights from 2006. Eur Urol 2007; Supl 6(12): 737–744.
29. Berger A, Steiner H, Stenzl A et al. Photodynamic therapy with intravesicalinstilation of 5-aminolevulinic acid for patiens with recurent superfitial bladder cancer: a single centre study. Urology 2003; 61(2): 338–341.
Labels
Paediatric urologist UrologyArticle was published in
Urological Journal
2011 Issue 3
Most read in this issue
- ILEAL NEOBLADDER AND ITS VARIANTS
- INTRAVESICAL INSTILLATION THERAPY IN THE TREATMENT OF SUPERFICIAL BLADDER CARCINOMA
- Treatment of muscle-invasive and metastatic bladder cancer – update of the EAU Guidelines
- METHODS OF NON-INVASIVE DIAGNOSTICS AND MONITORING OF URINARY BLADDER CANCER